Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Vertex (VERX) is one such stock that our proprietary system currently ... The company's annualized cash flow growth rate has been 42.8% over the past 3-5 years versus the industry average of ...

This was the stock's second consecutive day of losses.

Tracking the Wednesday's morning session, Vertex shares are trading at $50.62 ... A higher-than-average P/E ratio of 261.74 suggests caution, as the stock may be overvalued in the eyes of investors.

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $460, reflecting a -1.06% shift from the previouse trading day's closing. The stock trailed the S&P 500 ...